NeoGenomics Management
Management criteria checks 2/4
NeoGenomics' CEO is Tony Zook, appointed in Apr 2025, has a tenure of less than a year. directly owns 0.044% of the company’s shares, worth $648.31K. The average tenure of the management team and the board of directors is 1.6 years and 5.1 years respectively.
Key information
Tony Zook
Chief executive officer
US$320.4k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 1.6yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
NeoGenomics: Distribution Moat In Community Oncology
Jan 25Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Aug 27
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
Jul 30Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
May 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Mar 08NeoGenomics: Decent Fundamentals, But Still Overvalued
Feb 28Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Feb 18What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
Jan 14NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Nov 23Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Oct 16Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
Aug 01Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Jul 15Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues
Mar 30Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking
Dec 26CEO
Tony Zook (64 yo)
Mr. Anthony P. Zook, also known as Tony, serves as an Independent Director at Adaptin Bio Operating Corporation since February 2025. He is CEO of NeoGenomics, Inc. from April 1, 2025 and has been its Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$320.36k | 0.044% $ 648.3k | |
| President & COO | less than a year | US$3.18m | 0.094% $ 1.4m | |
| Chief Financial Officer | 3.2yrs | US$3.48m | 0.14% $ 2.0m | |
| Chief Digital & Information Officer | 1.1yrs | US$305.00k | 0.018% $ 268.4k | |
| Executive VP of Business Development | 3.8yrs | US$2.24m | 0.058% $ 857.1k | |
| Senior VP & Chief Accounting Officer | 2.8yrs | no data | 0.014% $ 200.1k | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| Vice President of Compliance & Privacy | less than a year | no data | no data | |
| Chief People & Culture Officer | no data | no data | no data | |
| Head of Strategy | 2.1yrs | no data | no data | |
| Chief Innovation Officer | no data | no data | no data | |
| Senior Vice President of Finance | no data | no data | no data |
Experienced Management: NEO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$320.36k | 0.044% $ 648.3k | |
| Independent Director | 5.6yrs | US$318.93k | 0.038% $ 557.8k | |
| Independent Director | 3.3yrs | US$310.88k | 0.034% $ 499.4k | |
| Independent Chair of the Board | 10.7yrs | US$370.10k | 0.062% $ 917.8k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Independent Director | 8.6yrs | US$312.05k | 0.040% $ 595.7k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | US$309.38k | 0.10% $ 1.5m | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data |
Experienced Board: NEO's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 20:57 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeoGenomics, Inc. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |